GRM1 Antibody / Metabotropic glutamate receptor 1 / mGluR1, 100ul

GRM1 antibody targets Metabotropic glutamate receptor 1 (GRM1), a member of the metabotropic glutamate receptor family that mediates glutamate-dependent signaling in the nervous system. GRM1 is a class C G protein-coupled receptor characterized by a large extracellular ligand-binding domain and a seven-transmembrane signaling region. The receptor is primarily localized to the plasma membrane of neurons, where it functions as a modulatory glutamate sensor rather than a fast ion channel. Through this role, GRM1 contributes to fine control of synaptic transmission and neuronal responsiveness.<br><br>Upon activation by glutamate, GRM1 couples mainly to Gq and G11 proteins, triggering intracellular signaling pathways that involve phospholipase C activation, inositol trisphosphate production, and intracellular calcium mobilization. These signaling events influence neuronal excitability, synaptic strength, and activity-dependent gene regulation. GRM1 signaling operates on slower time scales than ionotropic receptors, allowing it to shape long-term changes in synaptic function and neuronal network behavior. A GRM1 antibody supports research focused on receptor-mediated signaling mechanisms that underlie synaptic modulation and plasticity.<br><br>GRM1 expression is highly enriched in the cerebellum, particularly within Purkinje neurons, where it plays a critical role in motor coordination and cerebellar development. Outside the cerebellum, GRM1 is also expressed in hippocampal and cortical regions, contributing to learning, memory, and sensory integration. Its localization is often perisynaptic, positioning the receptor to respond to glutamate spillover during high synaptic activity. Analysis of GRM1 distribution and expression patterns provides insight into region-specific regulation of glutamatergic signaling in the brain.<br><br>From a disease and translational research perspective, GRM1 has been implicated in a range of neurological and neurodevelopmental conditions. Disruption of GRM1 signaling has been associated with movement disorders, ataxia, and cognitive dysfunction, reflecting its essential role in cerebellar and cortical circuits. GRM1 has also been studied in epilepsy and neuropsychiatric research, where altered glutamate signaling contributes to abnormal neuronal activity. In addition, aberrant GRM1 expression has been reported in certain cancers, highlighting broader roles for glutamate receptors outside the nervous system. Investigating GRM1 expression with a GRM1 antibody is therefore relevant to both neuroscience and disease-focused studies.<br><br>At the molecular level, the GRM1 gene encodes a large glycoprotein with a predicted core molecular weight of approximately 132 kDa. Due to extensive glycosylation and receptor dimerization, GRM1 is frequently observed at higher apparent molecular weights on SDS-PAGE. The receptor's extracellular domain is responsible for ligand recognition, while intracellular regions interact with scaffolding and signaling proteins that regulate receptor trafficking and signal specificity. A GRM1 antibody enables detection and analysis of GRM1 expression in research applications focused on glutamatergic signaling, synaptic regulation, and neurological disease mechanisms, with NSJ Bioreagents providing reagents intended for research use.

Specifications